{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:15:32Z","timestamp":1787242532029,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,9]],"date-time":"2017-04-09T00:00:00Z","timestamp":1491696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"St. Gallen Oncology Conferences"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ejca.2017.03.022","type":"journal-article","created":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T03:47:25Z","timestamp":1493437645000},"page":"41-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-4553","authenticated-orcid":false,"given":"Manfred P.","family":"Lutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Aust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco J.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus W.","family":"B\u00fcchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0000-1332","authenticated-orcid":false,"given":"Jean-Robert","family":"Delpero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Gloor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Glynne-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Hartwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Maisonneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mayerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Martignoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Neoptolemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Rhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno M.","family":"Schmied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seufferlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"van Laethem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.03.022_bib1","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1080\/0284186X.2016.1197419","article-title":"More deaths from pancreatic cancer than breast cancer in the EU by 2017","volume":"55","author":"Ferlay","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2017.03.022_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE\u20135-a population-based study","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib4","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2017.03.022_bib5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2017.03.022_bib6","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1002\/cncr.27636","article-title":"Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators","volume":"118","author":"Katz","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2017.03.022_bib7","unstructured":"Network NCC. NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma. Version 22016.https:\/\/www.nccn.org."},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2017.03.022_bib8","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","article-title":"Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)","volume":"155","author":"Bockhorn","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.ejca.2017.03.022_bib10","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1245\/s10434-015-4649-2","article-title":"Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy","volume":"22","author":"Evans","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib11","first-page":"1395","article-title":"[S3-guideline exocrine pancreatic cancer]","volume":"51","author":"Seufferlein","year":"2013","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.ejca.2017.03.022_bib12","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","article-title":"Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Balaban","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.gastro.2013.11.004","article-title":"Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association","volume":"146","author":"Al-Hawary","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2017.03.022_bib14","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1245\/s10434-008-0134-5","article-title":"Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma","volume":"15","author":"Maithel","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.hpb.2015.10.004","article-title":"Indications for staging laparoscopy in pancreatic cancer","volume":"18","author":"De Rosa","year":"2016","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ejca.2017.03.022_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/bjs.6043","article-title":"Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy","volume":"95","author":"Halloran","year":"2008","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2017.03.022_bib17","first-page":"CD009323","article-title":"Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer","volume":"7","author":"Allen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2017.03.022_bib18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s11605-014-2740-9","article-title":"What is the Significance of indeterminate pulmonary nodules in patients undergoing resection for pancreatic adenocarcinoma?","volume":"19","author":"Poruk","year":"2015","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ejca.2017.03.022_bib19","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/SLA.0000000000000719","article-title":"Natural history of preoperative subcentimeter pulmonary nodules in patients with resectable pancreatic adenocarcinoma: a retrospective cohort study","volume":"261","author":"Chang","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2017.03.022_bib20","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1136\/gutjnl-2015-311098","article-title":"Refinement of screening for familial pancreatic cancer","volume":"65","author":"Bartsch","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2017.03.022_bib21","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1136\/gutjnl-2014-308008","article-title":"A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals","volume":"65","author":"Harinck","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2017.03.022_bib22","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.2015.64.0730","article-title":"Benefit of Surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European Expert Centers","volume":"34","author":"Vasen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0903230","article-title":"Preoperative biliary drainage for cancer of the head of the pancreas","volume":"362","author":"van der Gaag","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.03.022_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12876-016-0460-1","article-title":"Role of preoperative biliary stents, bile contamination and antibiotic prophylaxis in surgical site infections after pancreaticoduodenectomy","volume":"16","author":"Gavazzi","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ejca.2017.03.022_bib25","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1136\/gutjnl-2014-308762","article-title":"Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer","volume":"65","author":"Tol","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2017.03.022_bib26","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.gie.2016.04.018","article-title":"Metal versus plastic stents for drainage of malignant biliary obstruction before primary surgical resection","volume":"84","author":"Song","year":"2016","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.ejca.2017.03.022_bib27","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.03.022_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2017.03.022_bib29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2017.03.022_bib30","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1200\/JCO.2010.30.3446","article-title":"Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012\/FFCD-9203\/GERCOR phase II study","volume":"28","author":"Van Laethem","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib31","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(01)06651-X","article-title":"Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial","volume":"358","author":"Neoptolemos","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2017.03.022_bib32","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2017.03.022_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.4007","article-title":"CONKO-005: adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks-A prospective randomized phase III study","volume":"33","author":"Sinn","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1053\/j.gastro.2012.06.006","article-title":"Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma","volume":"143","author":"Marechal","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2017.03.022_bib35","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.3390\/cancers2042001","article-title":"Definition of microscopic tumor clearance (r0) in pancreatic cancer resections","volume":"2","author":"Schlitter","year":"2010","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2017.03.022_bib36","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/00000658-200112000-00007","article-title":"Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and\/or chemotherapy in the ESPAC-1 randomized controlled trial","volume":"234","author":"Neoptolemos","year":"2001","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2017.03.022_bib37","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/bjs.9892","article-title":"Meta-analysis of radical resection rates and margin assessment in pancreatic cancer","volume":"102","author":"Chandrasegaram","year":"2015","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2017.03.022_bib38","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/SLA.0000000000001731","article-title":"Pancreatic cancer surgery: the new R-status counts","volume":"265","author":"Strobel","year":"2017","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2017.03.022_bib39","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1245\/s10434-008-9839-8","article-title":"Most pancreatic cancer resections are R1 resections","volume":"15","author":"Esposito","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib40","series-title":"Dataset for the histopathological reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct","author":"Physicians","year":"2010"},{"key":"10.1016\/j.ejca.2017.03.022_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/hpb.12061","article-title":"Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens","volume":"16","author":"Delpero","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ejca.2017.03.022_bib42","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/jclinpath-2012-201198","article-title":"Survey of UK histopathologists' approach to the reporting of resection specimens for carcinomas of the pancreatic head","volume":"66","author":"Feakins","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ejca.2017.03.022_bib43","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.surg.2011.07.006","article-title":"Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials","volume":"150","author":"Assifi","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.ejca.2017.03.022_bib44","doi-asserted-by":"crossref","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2017.03.022_bib45","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1200\/JCO.2016.68.5081","article-title":"Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis","volume":"35","author":"Mokdad","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib46","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1245\/s10434-010-0943-1","article-title":"Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation","volume":"17","author":"Katz","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib47","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1093\/annonc\/mdt239","article-title":"Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer","volume":"24","author":"Heinemann","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib48","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/SLA.0b013e3181cc90a3","article-title":"Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival","volume":"251","author":"Takahashi","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2017.03.022_bib49","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2017.03.022_bib50","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1245\/s10434-015-4647-4","article-title":"FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma","volume":"22","author":"Sadot","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2017.03.022_bib51","first-page":"1","article-title":"Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection","author":"Huguet","year":"2016","journal-title":"Acta Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917308407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917308407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T09:42:36Z","timestamp":1569145356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917308407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":51,"alternative-id":["S0959804917308407"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.03.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}